Developer docs
API playgroundTry for free, no card

Search company profiles

Faran

Full company profile

uuid0032igg

Namestring
Faran
Legal namestring
FARAN S.A.
Websiteurl
faran.gr
Company typeenum
Private
Founded yearint
1950
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersKifisiá, Greece
HQ citystring
Kifisiá
HQ countrystring
Greece
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
branded generics, biosimilar pharmaceuticals, specialty therapeutics, pharmaceutical distribution, injectable manufacturing
Industry5 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Faran generates revenue through the sale of branded generics, original, biosimilar, and generic pharmaceutical products across Greece. The company has a portfolio covering Oncology, Haematology, Nephrology, Rheumatology, Endocrinology, Virology, Gynaecology, Pulmonology, Cardiology, and Andrology. The company has achieved consistent sales growth, with 40% growth in 2020, over 20% in 2021, and 30% in 2022, outperforming the broader Greek pharmaceutical market during a period of stagnant public pharmaceutical spending.

faran.gr
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Infrastructure, Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Faran S.A. is a Greek pharmaceutical company that develops, produces, and distributes branded generics, original, biosimilar, and generic pharmaceutical products across ten therapeutic areas: Oncology, Haematology, Nephrology, Rheumatology, Endocrinology, Andrology, Virology, Gynaecology, Pulmonology, and Cardiology. The company operates GMP-certified manufacturing and distribution facilities in Greece and combines in-house products with exclusive distribution rights for products from international pharmaceutical partners including Novartis, Sandoz, STADA, IBSA, BESIN, Meiji, and Quantum Genomics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 90.8% EBITDA growth rate (2018-2021), ranked third highest among FortuneGreece's 30 fastest-growing companies in 2022
+2 more records
Product overview1 text field

FARAN is a Greek pharmaceutical company with 70 years of history offering a portfolio of branded generics, original products, and biosimilars. The therapeutic portfolio covers Oncology, Haematology, Nephrology, Rheumatology, Endocrinology, Pathology, Gynaecology, Virology, Cardiology, and Immunology. The company operates through a combination of in-house branded generics and exclusive distribution partnerships with international pharmaceutical companies including Novartis (Tyverb, Zykadia), Sandoz (Epoetin Alfa), STADA (Movymia biosimilar), Meiji (Spectracef), IBSA, Besins, Quantum Genomics (Firibastat), and others. Currently developing an innovative Nintedanib oral solution through EU-funded industrial research. Products are available to healthcare professionals through registration on the company website.

Product and service7 records
1Firibastat
CategoryCardiology / Hypertension
Description

Innovative pharmaceutical product (BAPAI — Brain Aminopeptidase A Inhibitor) in Phase 3 clinical studies for the treatment of resistant hypertension and heart failure. Developed in partnership with Quantum Genomics and distributed in Greece by Faran.

2Tyverb (Lapatinib)
CategoryOncology
Description

Pharmaceutical product indicated for the treatment of metastatic breast cancer that overexpresses HER2. Distributed in Greece through partnership with Novartis (Hellas) S.A.

3Zykadia (Ceritinib)
CategoryOncology
Description

Pharmaceutical product indicated for the treatment of non-small cell lung cancer presenting ALK rearrangement. Distributed in Greece through partnership with Novartis (Hellas) S.A.

4Movymia (Teriparatide biosimilar)
CategoryRheumatology / Endocrinology
Description

Biosimilar Teriparatide product for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures. Distributed in Greece through partnership with STADA Arzneimittel AG.

5Spectracef (Ceftidoren Pivoxil)
CategoryAnti-infectives / Pulmonology
Description

3rd generation oral cephalosporin antibiotic for the treatment of community-acquired respiratory infections and simple soft tissue infections. Distributed in Greece through partnership with Meiji.

6Epoetin Alfa
CategoryHaematology / Nephrology
Description

Biotech product for the treatment of anemia-related conditions. Distributed in Greece through an expanded partnership with Sandoz (a Novartis Group company).

7Nintedanib Oral Solution
CategoryR&D Product / Pulmonology / Oncology
Description

Novel oral solution formulation of Nintedanib (a triple angiokinase inhibitor targeting VEGFR, PDGFR, and FGFR) being developed by Faran for idiopathic pulmonary fibrosis (IPF) and certain types of non-small cell lung cancer, combining indications of Ofev and Vargatef in a single pharmaceutical form.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-30
Description

Faran entered an exclusive partnership with Quantum Genomics on June 30, 2021, for the development and distribution of Firibastat — an innovative pharmaceutical product targeting resistant hypertension and heart failure. Firibastat is a Brain Aminopeptidase A Inhibitor (BAPAI) that represents a truly innovative therapeutic platform. The product was in Phase 3 clinical studies with encouraging early results. Faran holds exclusive licensing and distribution rights for the Greek market. This is the first in a series of planned cardiology collaborations for Faran.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Faran partnered with STADA Arzneimittel AG to promote and distribute Movymia (Teriparatide biosimilar) in the Greek market for the treatment of osteoporosis in postmenopausal women and men at increased fracture risk. This collaboration strengthens Faran's leadership position in the field of Biotechnology among Greek pharmaceutical companies, as STADA is a global leader in biosimilar research, development, and manufacturing.

3Sandoz (Novartis Group)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Faran expanded its partnership with Sandoz (a member of the Novartis Group) to promote and distribute a product containing Epoetin Alfa in the Greek market. Following successful prior collaboration, this expanded partnership further strengthens Faran's leadership position in the field of biotechnology, as Sandoz is a global leader in biosimilar research, development, and manufacturing.

faran.gr
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Faran entered a collaboration with Novartis (Hellas) S.A. for the promotion and distribution of Tyverb (Lapatinib) for metastatic breast cancer HER2-positive patients, and Zykadia (Ceritinib) for ALK-positive non-small cell lung cancer treatment in the Greek market. This collaboration strengthens Faran's leading position in the field of therapeutic oncology among Greek pharmaceutical companies.

5Meiji
Strategic tierSecondaryTypeChannel Partner/ Reseller/ Distributor
Description

Faran partnered with the Japanese pharmaceutical company Meiji for the distribution of Spectracef (Ceftidoren Pivoxil), a 3rd generation oral cephalosporin antibiotic for the treatment of community-acquired respiratory tract infections and simple soft tissue infections in the Greek market. Meiji is a major Japanese pharmaceutical company focused on infectious disease treatments.

faran.gr
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

In 2022, Faran signed agreements with IBSA (Switzerland) and BESIN (France) — major companies in the field of gynaecology and assisted reproduction. Faran covers both the stimulation stage (with gonadotropins) and the luteal phase support stage (with progesterone) for women facing conception difficulties, making it a key player in the assisted reproduction market in Greece.

7BESIN (France)
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

In 2022, Faran signed agreements with IBSA (Switzerland) and BESIN (France) — major companies in the field of gynaecology and assisted reproduction. Faran covers both the stimulation stage (with gonadotropins) and the luteal phase support stage (with progesterone) for women facing conception difficulties, making it a key player in the assisted reproduction market in Greece.

faran.gr
8Atnhas
Strategic tierSecondaryTypeChannel Partner/ Reseller/ Distributor
Description

Faran partnered with the pharmaceutical company Atnhas for the distribution of Bonviva (Ibandronic Acid) in the field of osteoporosis. Bonviva is used to treat osteoporosis in postmenopausal women at risk of fractures. Ibandronic acid is a high-potency bisphosphonate belonging to the nitrogen-containing bisphosphonate group, which selectively acts on bone tissue by specifically inhibiting osteoclast activity.

faran.gr
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Greek pharma manufacturer focused on branded generics and specialty therapeutics, serving Greek healthcare professionals through a comparable sales-led model. Closely comparable domestic specialty pharma peer.

TypeDirect peer
Description

Greek-headquartered pharmaceutical company developing and supplying generics and specialty products, with a much larger international generics footprint. Comparable in therapeutic breadth and Greek origin, but materially larger scale.

3Specifar Pharmaceuticals
TypeDirect peer
Description

Greek generics and specialty pharmaceutical manufacturer, now part of the broader Teva ecosystem. Highly comparable in branded-generics distribution and Greek-market presence.

TypeDirect peer
Description

Greek pharma company with branded generics, OTC, and consumer health offerings. Direct Greek-market peer with similar sales-led healthcare-professional engagement model.

TypeBroad incumbent
Description

Italian-headquartered mid-large specialty pharma group; historically acquired FARAN's commercial operations. Comparable specialty-pharma footprint across Southern Europe and similar branded-generics + specialty distribution model.

TypeDirect peer
Description

Greek generics and specialty pharma manufacturer; co-investor with Faran in the Tripoli industrial park and overlapping therapeutic areas including injectables. Same domestic-market positioning and Greek-pharma regulatory context.

TypeDirect peer
Description

Greek pharmaceutical company with a similarly broad specialty portfolio (cardiology, oncology, respiratory, antibiotics) and co-investor in Faran's Tripoli facility through its Win Medica subsidiary. Closest direct structural peer in Greece.

TypeDirect peer
Description

Greek pharmaceutical company operating in branded generics, specialty pharma, and injectables with manufacturing in Greece. Overlapping therapeutic categories and Greek-market sales-led go-to-market.

TypeEmerging player
Description

Swiss specialty pharma with leadership in reproductive medicine, endocrinology, and gynaecology — the exact therapeutic categories where Faran is its Greek partner. Closely comparable in endocrinology/IVF positioning.

TypeDirect peer
Description

European-focused generics and specialty pharma group with a leading biosimilar portfolio; Faran is STADA's Greek distributor for Movymia. Comparable biosimilar/specialty distribution model and partner-style go-to-market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Faran

Pharmaceuticalsfaran.gr

Faran firmographics

Firmographics
Name
Faran
Legal name
FARAN S.A.
Website
https://faran.gr
Company type
Private
Founded year
1950
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Faran industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRAOAHAD
Specialty Pharmacy & Biologics Distribution

Keywords

  • Branded generics
  • Biosimilar pharmaceuticals
  • Specialty therapeutics
  • Pharmaceutical distribution
  • Injectable manufacturing

Where Faran is headquartered

Location

Headquarters

HQ city
Kifisiá
HQ country
Greece
HQ region
Europe

Offices2 records

Markets served

Faran business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Infrastructure, Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Pharmaceutical Product Sales: Faran generates revenue through the sale of branded generics, original, biosimilar, and generic pharmaceutical products across Greece. The company has a portfolio covering Oncology, Haematology, Nephrology, Rheumatology, Endocrinology, Virology, Gynaecology, Pulmonology, Cardiology, and Andrology. The company has achieved consistent sales growth, with 40% growth in 2020, over 20% in 2021, and 30% in 2022, outperforming the broader Greek pharmaceutical market during a period of stagnant public pharmaceutical spending.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Faran product offering

Product offering

Core offering

Faran S.A. is a Greek pharmaceutical company that develops, produces, and distributes branded generics, original, biosimilar, and generic pharmaceutical products across ten therapeutic areas: Oncology, Haematology, Nephrology, Rheumatology, Endocrinology, Andrology, Virology, Gynaecology, Pulmonology, and Cardiology. The company operates GMP-certified manufacturing and distribution facilities in Greece and combines in-house products with exclusive distribution rights for products from international pharmaceutical partners including Novartis, Sandoz, STADA, IBSA, BESIN, Meiji, and Quantum Genomics.

Product overview

FARAN is a Greek pharmaceutical company with 70 years of history offering a portfolio of branded generics, original products, and biosimilars. The therapeutic portfolio covers Oncology, Haematology, Nephrology, Rheumatology, Endocrinology, Pathology, Gynaecology, Virology, Cardiology, and Immunology. The company operates through a combination of in-house branded generics and exclusive distribution partnerships with international pharmaceutical companies including Novartis (Tyverb, Zykadia), Sandoz (Epoetin Alfa), STADA (Movymia biosimilar), Meiji (Spectracef), IBSA, Besins, Quantum Genomics (Firibastat), and others. Currently developing an innovative Nintedanib oral solution through EU-funded industrial research. Products are available to healthcare professionals through registration on the company website.

Differentiator

Problem solved

Functional benefit

Products and services

  • Firibastat Innovative pharmaceutical product (BAPAI — Brain Aminopeptidase A Inhibitor) in Phase 3 clinical studies for the treatment of resistant hypertension and heart failure. Developed in partnership with Quantum Genomics and distributed in Greece by Faran.
  • Tyverb (Lapatinib) Pharmaceutical product indicated for the treatment of metastatic breast cancer that overexpresses HER2. Distributed in Greece through partnership with Novartis (Hellas) S.A.
  • Zykadia (Ceritinib) Pharmaceutical product indicated for the treatment of non-small cell lung cancer presenting ALK rearrangement. Distributed in Greece through partnership with Novartis (Hellas) S.A.
  • Movymia (Teriparatide biosimilar) Biosimilar Teriparatide product for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures. Distributed in Greece through partnership with STADA Arzneimittel AG.
  • Spectracef (Ceftidoren Pivoxil) 3rd generation oral cephalosporin antibiotic for the treatment of community-acquired respiratory infections and simple soft tissue infections. Distributed in Greece through partnership with Meiji.
  • Epoetin Alfa Biotech product for the treatment of anemia-related conditions. Distributed in Greece through an expanded partnership with Sandoz (a Novartis Group company).
  • Nintedanib Oral Solution Novel oral solution formulation of Nintedanib (a triple angiokinase inhibitor targeting VEGFR, PDGFR, and FGFR) being developed by Faran for idiopathic pulmonary fibrosis (IPF) and certain types of non-small cell lung cancer, combining indications of Ofev and Vargatef in a single pharmaceutical form.

Quantifiable outcome

  • 90.8% EBITDA growth rate (2018-2021), ranked third highest among FortuneGreece's 30 fastest-growing companies in 2022
  • +2 more outcomes

Companies that use Faran

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Faran technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Faran partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and secondary.

  • Quantum GenomicscoreStrategic or Co-development Partner · 30 June 2021Faran entered an exclusive partnership with Quantum Genomics on June 30, 2021, for the development and distribution of Firibastat — an innovative pharmaceutical product targeting resistant hypertension and heart failure. Firibastat is a Brain Aminopeptidase A Inhibitor (BAPAI) that represents a truly innovative therapeutic platform. The product was in Phase 3 clinical studies with encouraging early results. Faran holds exclusive licensing and distribution rights for the Greek market. This is the first in a series of planned cardiology collaborations for Faran.
  • STADA Arzneimittel AGcoreChannel Partner/ Reseller/ DistributorFaran partnered with STADA Arzneimittel AG to promote and distribute Movymia (Teriparatide biosimilar) in the Greek market for the treatment of osteoporosis in postmenopausal women and men at increased fracture risk. This collaboration strengthens Faran's leadership position in the field of Biotechnology among Greek pharmaceutical companies, as STADA is a global leader in biosimilar research, development, and manufacturing.
  • Sandoz (Novartis Group)coreChannel Partner/ Reseller/ DistributorFaran expanded its partnership with Sandoz (a member of the Novartis Group) to promote and distribute a product containing Epoetin Alfa in the Greek market. Following successful prior collaboration, this expanded partnership further strengthens Faran's leadership position in the field of biotechnology, as Sandoz is a global leader in biosimilar research, development, and manufacturing.
  • Novartis (Hellas) S.A.coreChannel Partner/ Reseller/ DistributorFaran entered a collaboration with Novartis (Hellas) S.A. for the promotion and distribution of Tyverb (Lapatinib) for metastatic breast cancer HER2-positive patients, and Zykadia (Ceritinib) for ALK-positive non-small cell lung cancer treatment in the Greek market. This collaboration strengthens Faran's leading position in the field of therapeutic oncology among Greek pharmaceutical companies.
  • MeijisecondaryChannel Partner/ Reseller/ DistributorFaran partnered with the Japanese pharmaceutical company Meiji for the distribution of Spectracef (Ceftidoren Pivoxil), a 3rd generation oral cephalosporin antibiotic for the treatment of community-acquired respiratory tract infections and simple soft tissue infections in the Greek market. Meiji is a major Japanese pharmaceutical company focused on infectious disease treatments.
  • IBSA (Swiss)coreChannel Partner/ Reseller/ DistributorIn 2022, Faran signed agreements with IBSA (Switzerland) and BESIN (France) — major companies in the field of gynaecology and assisted reproduction. Faran covers both the stimulation stage (with gonadotropins) and the luteal phase support stage (with progesterone) for women facing conception difficulties, making it a key player in the assisted reproduction market in Greece.
  • BESIN (France)coreChannel Partner/ Reseller/ DistributorIn 2022, Faran signed agreements with IBSA (Switzerland) and BESIN (France) — major companies in the field of gynaecology and assisted reproduction. Faran covers both the stimulation stage (with gonadotropins) and the luteal phase support stage (with progesterone) for women facing conception difficulties, making it a key player in the assisted reproduction market in Greece.
  • AtnhassecondaryChannel Partner/ Reseller/ DistributorFaran partnered with the pharmaceutical company Atnhas for the distribution of Bonviva (Ibandronic Acid) in the field of osteoporosis. Bonviva is used to treat osteoporosis in postmenopausal women at risk of fractures. Ibandronic acid is a high-potency bisphosphonate belonging to the nitrogen-containing bisphosphonate group, which selectively acts on bone tissue by specifically inhibiting osteoclast activity.

Scale indicators6 records

Recent moves8 records

Expansion highlights7 records

Faran competitors and assessment

Company assessment

Direct peers

  • Help Pharmaceuticals: Greek pharma manufacturer focused on branded generics and specialty therapeutics, serving Greek healthcare professionals through a comparable sales-led model. Closely comparable domestic specialty pharma peer.
  • Pharmathen: Greek-headquartered pharmaceutical company developing and supplying generics and specialty products, with a much larger international generics footprint. Comparable in therapeutic breadth and Greek origin, but materially larger scale.
  • Specifar Pharmaceuticals: Greek generics and specialty pharmaceutical manufacturer, now part of the broader Teva ecosystem. Highly comparable in branded-generics distribution and Greek-market presence.
  • Galenica: Greek pharma company with branded generics, OTC, and consumer health offerings. Direct Greek-market peer with similar sales-led healthcare-professional engagement model.
  • DEMO Pharmaceuticals: Greek generics and specialty pharma manufacturer; co-investor with Faran in the Tripoli industrial park and overlapping therapeutic areas including injectables. Same domestic-market positioning and Greek-pharma regulatory context.
  • ELPEN Pharmaceuticals: Greek pharmaceutical company with a similarly broad specialty portfolio (cardiology, oncology, respiratory, antibiotics) and co-investor in Faran's Tripoli facility through its Win Medica subsidiary. Closest direct structural peer in Greece.
  • Rafarm: Greek pharmaceutical company operating in branded generics, specialty pharma, and injectables with manufacturing in Greece. Overlapping therapeutic categories and Greek-market sales-led go-to-market.
  • STADA Arzneimittel: European-focused generics and specialty pharma group with a leading biosimilar portfolio; Faran is STADA's Greek distributor for Movymia. Comparable biosimilar/specialty distribution model and partner-style go-to-market.

Broad incumbents

  • Angelini Pharma: Italian-headquartered mid-large specialty pharma group; historically acquired FARAN's commercial operations. Comparable specialty-pharma footprint across Southern Europe and similar branded-generics + specialty distribution model.

Emerging players

  • IBSA (Institut Biochimique SA): Swiss specialty pharma with leadership in reproductive medicine, endocrinology, and gynaecology — the exact therapeutic categories where Faran is its Greek partner. Closely comparable in endocrinology/IVF positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Faran social profiles

Digital presence

Faran compliance and trust

Trust signal

Compliance5 records

Faran financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Faran leadership team

Management profile

Number of profiles

Profiles2 records

Faran funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Faran M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Faran

What does Faran do?

Faran S.A. is a Greek pharmaceutical company that develops, produces, and distributes branded generics, original, biosimilar, and generic pharmaceutical products across ten therapeutic areas: Oncology, Haematology, Nephrology, Rheumatology, Endocrinology, Andrology, Virology, Gynaecology, Pulmonology, and Cardiology. The company operates GMP-certified manufacturing and distribution facilities in Greece and combines in-house products with exclusive distribution rights for products from international pharmaceutical partners including Novartis, Sandoz, STADA, IBSA, BESIN, Meiji, and Quantum Genomics.

Is Faran a public or private company?

Faran is a private company. It is classified as family owned and is currently operating.

When was Faran founded?

Faran was founded in 1950. It employs 51 to 100 people.

Where is Faran based?

Faran is headquartered in Kifisiá, Greece, in the Europe region.

How does Faran make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Faran's main competitors?

Direct peers on record are Help Pharmaceuticals, Pharmathen, Specifar Pharmaceuticals, Galenica, DEMO Pharmaceuticals, ELPEN Pharmaceuticals, Rafarm and STADA Arzneimittel. Angelini Pharma is listed as a broad incumbent. IBSA (Institut Biochimique SA) is listed as an emerging player.

Does Faran have an API?

No public API is recorded for Faran.

What industry is Faran in?

Faran's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals